The layoffs, set to take place between Dec. 10 and April 2, are a result of a contract manufacturing agreement ending in January.
After the layoffs, 160 employees will remain at the facility, according to a company spokesperson.
“We have a loyal and committed workforce at our Memphis site, and this decision is no reflection on the team or their performance,” Glaxo spokesperson Caryn Previdi told the Commercial Appeal. “Teams at the Memphis site have demonstrated a great level of commitment to the business, and we very much appreciate their dedication and hard work.”
More articles on pharmacy:
20 generic drugmakers must answer price-fixing lawsuit
Novartis strikes $2.1B deal to buy cancer drugmaker Endocyte
Insys tactics to hike fentanyl sales detailed in Missouri senator’s report
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
